Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05035277
Other study ID # 247400
Secondary ID 2021-001554-61
Status Recruiting
Phase Phase 3
First received
Last updated
Start date December 4, 2021
Est. completion date November 2026

Study information

Verified date November 2022
Source Oslo University Hospital
Contact Øyvind H Lie, MD, PhD
Phone +4793429011
Email oyvlie@gmail.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

ACASA-TAVI is a pragmatic randomized controlled trial assessing the value of anticoagulation therapy versus the standard antiplatelet therapy after transcatheter aortic valve implantation in patients with aortic stenosis. The trial will assess the efficacy of direct oral anticoagulation (DOAC) therapy compared to the standard single antiplatelet therapy to prevent degeneration of the valve and its safety in co-primary endpoints with blinded endpoint adjudication. The effect of DOAC therapy on hard clinical outcomes will be assessed during long-term follow-up.


Description:

Aortic stenosis is a highly prevalent valvular disease and an important cause of morbidity and mortality in the elderly population. Transcatheter aortic valve implantation (TAVI) is an effective intervention in patients with severe aortic stenosis and low surgical risk. The procedure is highly effective, safe, and widely implemented. Current recommendations support transcatheter treatment of younger patients, including patients from 65 years of age with low surgical risk. This practice increases the importance of long-term valve maintenance. Observational data have suggested that early signs of valve degeneration (i.e. hypo-attenuated leaflet thickening/thrombosis/reduced leaflet motion) are associated with an increased risk of embolic events. This is an increasing problem with emerging indications in younger populations. Because both ischemic and bleeding complications after TAVI can be life-threatening, it is important to establish the optimal anti-thrombotic treatment regime. Use of oral anticoagulation after implantation for bioprosthetic valves have been associated with resolved valve degeneration and possible favourable clinical effects. The current practice guidelines recommend that oral anticoagulation may be considered for 3 months after open surgical bioprosthetic valve implantation. Patients with an independent indication for oral anticoagulation (i.e. atrial fibrillation or venous thromboembolism) are recommended to continue this treatment lifelong, but there is no recommendation for oral anticoagulation following TAVI in patients without other indications. In patients without indication for oral anticoagulation, the use of double anti-platelet therapy for 3-6 months following TAVI is recommended. However, single anti-platelet therapy with acetylsalicylic acid (ASA) without clopidogrel has been reported to improve bleeding outcomes and a composite of bleeding and ischemic outcomes. The effect of on oral anticoagulation-based treatment strategy compared to the standard single anti-platelet treatment strategy for valve maintenance after TAVI is unknown. Increased anti-thrombotic treatment intensity may come at the cost of increased bleeding risk. Dual anti-platelet therapy and combination therapy with anticoagulation and anti-platelet therapy have both been associated with unfavourable outcomes. Combined anti-platelet and anti-coagulation treatment has been shown to reduce valve degeneration at the cost of increased bleeding. Conversely, single anti-platelet therapy and anti-coagulation with a direct oral anti-coagulant (DOAC) have been associated with similar bleeding risk. Bleeding rates in patients treated with anti-coagulation after TAVI have been reported to be slightly higher than in patients treated with ASA after TAVI, but patients with conventional indications for anti-coagulation have higher baseline bleeding risk than those without such indications. Therefore, the risk of bleeding in patients treated with DOAC or ASA following TAVI may be similar, but no randomized trials have been performed. ACASA-TAVI will include 360 patients > 65 years and < 80 years of age who have undergone successful TAVI and have no conventional indication for DOAC in a prospective randomized open-label blinded-endpoint (PROBE) study. The intervention arm will be 12 month therapy with an anti-Xa type DOAC (without antiplatelet therapy) and the active control arm will be standard dose ASA. After 12 months, the intervention group will be switched to ASA maintenance. All patients will undergo clinical assessment, cardiac CT and echocardiography at 12 months with blinded endpoint adjudication by an independent committee. Outcome measures will comply with the Valve Academic Research Consortium 3 (VARC-3) consensus, and are described in detail in the protocol. The co-primary endpoints at 12 months, hypo-attenuated leaflet thickening (HALT) and safety composite, must both be met for the trial to declare success. The effect of the DOAC therapy on long-term major adverse cardiovascular events (MACE) will be assessed after 5 years and 10 years.


Recruitment information / eligibility

Status Recruiting
Enrollment 360
Est. completion date November 2026
Est. primary completion date November 2026
Accepts healthy volunteers No
Gender All
Age group 65 Years to 80 Years
Eligibility Inclusion Criteria: - Successful trans-catheter aortic valve implantation in patients aged >65 and <80 years old at the time of the procedure. Exclusion Criteria: - Strict indication for anticoagulation or anti-platelet drugs - Strict contraindication for anticoagulation or anti-platelet drugs - Overt cognitive failure - Failure to obtain written informed consent - Concomitant use of inducers or inhibitors of CYP3A4 or P-glycoprotein

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Acetylsalicylic acid
Acetylsalicylic acid 75 mg once daily is the current standard-of-care in TAVI patients without other indications for anticoagulation therapy.
Apixaban
Standard dose apixaban will be one of the options for the patients in the experimental arm.
Rivaroxaban
Standard dose rivaroxaban will be one of the options for the patients in the experimental arm.
Edoxaban
Standard dose edoxaban will be one of the options for the patients in the experimental arm.

Locations

Country Name City State
Norway Haukeland University Hospital Bergen
Norway Oslo University Hospital - Rikshospitalet Oslo
Norway Oslo Univesity Hospital - Ullevål Oslo

Sponsors (2)

Lead Sponsor Collaborator
Oslo University Hospital University of Oslo

Country where clinical trial is conducted

Norway, 

References & Publications (1)

VARC-3 WRITING COMMITTEE, Généreux P, Piazza N, Alu MC, Nazif T, Hahn RT, Pibarot P, Bax JJ, Leipsic JA, Blanke P, Blackstone EH, Finn MT, Kapadia S, Linke A, Mack MJ, Makkar R, Mehran R, Popma JJ, Reardon M, Rodes-Cabau J, Van Mieghem NM, Webb JG, Cohen DJ, Leon MB. Valve Academic Research Consortium 3: updated endpoint definitions for aortic valve clinical research. Eur Heart J. 2021 May 14;42(19):1825-1857. doi: 10.1093/eurheartj/ehaa799. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Other CT signs of valve degeneration Exploratory outcome. Any evidence of reduced leaflet mobility, hypo-attenuated leaflet thickening or thrombus. 12 months
Other Echocardiographic signs of valve degeneration Exploratory outcome. Change in transaortic pressure gradient assessed by echocardiography. 12 months
Other Cardiac function Exploratory outcome. Change in left ventricular global longitudinal strain assessed by echocardiography. 12 months
Other Non-procedure-related life-threatening or disabling bleeding Exploratory outcome. VARC-3 definition. 12 months
Other Number of major adverse clinical events Exploratory outcome. Defined as stroke or transient ischemic attack of any cause, myocardial infarction, re-intervention on the aortic valve, death (cardiac, all-cause, non-cardiac) and heart failure hospitalization 12 months
Other Troponin T Exploratory outcome. Assessment of blood samples. 12 months
Other N-terminal pro-B-type natriuretic peptide Exploratory outcome. Assessment of blood samples. 12 months
Other Infective endocarditis Exploratory outcome. Definition by Duke criteria. 12 months
Other Change in quality of life - Kansas City Cardiomyopathy Questionnaire Exploratory outcome. Assessed by change in the Kansas City Cardiomyopathy Questionnaire (KCCQ) score (score 0-100, Higher value indicates better quality of life). 12 months
Other Cognitive function Exploratory outcome. Assessed by change in the Mini-cog score 12 months
Other Clinical efficacy Composite of of Freedom from all-cause mortality, Freedom from all stroke, Freedom from hospitalization for procedure- or valve-related causes, Freedom from KCCQ overall summary score <45 or decline from baseline of >10 points. Intention-to-treat, superiority. 5 years
Other All-cause mortality Fifth hierarchical secondary outcome. Intention-to-treat population. 5 years
Other Echocardiographic signs of valve degeneration Exploratory outcome. Change in transaortic pressure gradient assessed by echocardiography. 5 years
Other Cardiac function Exploratory outcome. Change in left ventricular global longitudinal strain assessed by echocardiography. 5 years
Other N-terminal pro-B-type natriuretic peptide Exploratory outcome. Assessment of blood samples. 5 years
Other Troponin T Exploratory outcome. Assessment of blood samples. 5 years
Other Individual components of MACE Exploratory outcome. Assessment of the individual components of MACE (the primary outcome at long-term follow-up). 5 years
Other Change in quality of life - Kansas City Cardiomyopathy Questionnaire Exploratory outcome. Assessed by change in the Kansas City Cardiomyopathy Questionnaire (KCCQ) score (score 0-100, Higher value indicates better quality of life). 5 years
Other Cognitive function Exploratory outcome. Assessed by change in the Mini-cog score 5 years
Other Infective endocarditis Exploratory outcome. Definition by Duke criteria. 5 years
Other Clinical efficacy Composite of of Freedom from all-cause mortality, Freedom from all stroke, Freedom from hospitalization for procedure- or valve-related causes, Freedom from KCCQ overall summary score <45 or decline from baseline of >10 points. Intention-to-treat, superiority. 10 years
Other All-cause mortality Fifth hierarchical secondary outcome. Intention-to-treat population. 10 years
Other Echocardiographic signs of valve degeneration Exploratory outcome. Change in transaortic pressure gradient assessed by echocardiography. 10 years
Other Cardiac function Exploratory outcome. Change in left ventricular global longitudinal strain assessed by echocardiography. 10 years
Other N-terminal pro-B-type natriuretic peptide Exploratory outcome. Assessment of blood samples. 10 years
Other Troponin T Exploratory outcome. Assessment of blood samples. 10 years
Other Individual components of MACE Exploratory outcome. Assessment of the individual components of MACE (the primary outcome at long-term follow-up). 10 years
Other Change in quality of life - Kansas City Cardiomyopathy Questionnaire Exploratory outcome. Assessed by change in the Kansas City Cardiomyopathy Questionnaire (KCCQ) score (score 0-100, Higher value indicates better quality of life). 10 years
Other Cognitive function Exploratory outcome. Assessed by change in the Mini-cog score 10 years
Other Infective endocarditis Exploratory outcome. Definition by Duke criteria. 10 years
Primary Hypo-attenuated leaflet thickening First co-primary endpoint. The presence of hypo-attenuated leaflet thickening on dedicated cardiac CT after 12 months will be registered by a blinded expert reader. Intention-to-treat, superiority. 12 months
Primary Safety composite - Incidence of Treatment Emergent Adverse Clinical Outcome Second co-primary outcome. Composite of VARC-3 bleeding events, thromboembolic events (myocardial infarction or stroke) and all-cause mortality. Per-protocol, non-inferiority. 12 months
Primary Major adverse cardiovascular events (MACE) Primary outcome during long-term follow-up. The rate of the composite of Cardiac death, Aortic valve re-intervention, Stroke, Myocardial infarction, Heart failure hospitalization and Major, life-threatening, or disabling bleeding. 5 years
Primary Major adverse cardiovascular events (MACE) Primary outcome during long-term follow-up. The rate of the composite of Cardiac death, Aortic valve re-intervention, Stroke, Myocardial infarction, Heart failure hospitalization and Major, life-threatening, or disabling bleeding. 10 years
Secondary Clinical efficacy First hierarchical secondary outcome. Composite of of Freedom from all-cause mortality, Freedom from all stroke, Freedom from hospitalization for procedure- or valve-related causes, Freedom from KCCQ overall summary score <45 or decline from baseline of >10 points. Intention-to-treat, superiority. 12 months
Secondary Safety composite, superiority Second hierarchical secondary outcome. Composite of VARC-3 bleeding events, thromboembolic events (myocardial infarction or stroke) and all-cause mortality. Same endpoint as second co-primary outcome, but intention-to-treat, superiority. 12 months
Secondary Thromboembolic events Third hierarchical secondary outcome. Composite of myocardial infarction or stroke of any cause. Intention-to-treat population. 12 months
Secondary Bleeding events Fourth hierarchical secondary outcome. Bleeding events according to VARC-3 definitions. Intention-to-treat population. 12 months
Secondary All-cause mortality Fifth hierarchical secondary outcome. Intention-to-treat population. 12 months
Secondary The number of adverse events First secondary safety endpoint. Safety population. 12 months
Secondary The number of serious adverse events Second secondary safety endpoint. Safety population. 12 months
Secondary Life-threatening or disabling bleeding Third secondary safety endpoint. Safety population. VARC-3 definition. 12 months
Secondary Major bleeding Fourth secondary safety endpoint. Safety population. VARC-3 definition. 12 months
Secondary Minor bleeding Fifth secondary safety endpoint. Safety population. VARC-3 definition. 12 months
See also
  Status Clinical Trial Phase
Recruiting NCT04310046 - Optimal Timing of Transcatheter Aortic Valve Implantation and Percutaneous Coronary Intervention - The TAVI PCI Trial N/A
Recruiting NCT06008080 - Post-Market Clinical Follow Up Study With Navitor Valve
Recruiting NCT06055751 - Long Term Evaluation of Cardiac Arrhythmias After Transcatheter Aortic Valve Implantation -The LOCATE Registry
Active, not recruiting NCT04815785 - Safety and Efficacy of TaurusOne® Transcatheter Aortic Valve System in Patients With Severe Calcific Aortic Stenosis N/A
Terminated NCT02202434 - Safety and Efficacy Study of Lotus Valve for Transcatheter Aortic Valve Replacement N/A
Recruiting NCT03029026 - The Role of Occult Cardiac Amyloid in the Elderly With Aortic Stenosis.
Active, not recruiting NCT02903420 - A Clinical Trial of Transcatheter Aortic Valves in Dialysis Patients (Japan) N/A
Completed NCT02629328 - CardioCel Tri-leaflet Repair Study N/A
Completed NCT02306226 - Symetis ACURATE Neo™ Valve Implantation SAVI TF Registry
Withdrawn NCT01648309 - Neuropsychological Testing in Patients Undergoing Transvascular Aortic Valve Implantation N/A
Completed NCT01676727 - ADVANCE Direct Aortic Study
Completed NCT01422044 - Risk Prediction in Aortic Stenosis N/A
Withdrawn NCT00774657 - Ventricular Remodeling In Patients With Aortic Stenosis Assessed Echocardiography N/A
Terminated NCT00535899 - Speckle Tracking Imaging in Patients With Low Ejection Fraction Aortic Stenosis (SPArKLE-AS) N/A
Terminated NCT05070130 - OpSens PRIME CLASS
Completed NCT03314857 - China XT: Safety and Effectiveness of Edwards Lifesciences SAPIEN XT THV in the Chinese Population N/A
Completed NCT04157920 - Impact of Predilatation Between Self-expanding Valves N/A
Enrolling by invitation NCT06212050 - Feasibility, Safety, and Effectiveness of the ACURATE neo2 Transcatheter Heart Valve for Severe Bicuspid Aortic Stenosis
Recruiting NCT05893082 - Multicenter Feasibility Trial of the F2 Filter and Delivery System for Embolic Protection During TAVR N/A
Completed NCT03250806 - Early Detection of Aortic Stenosis in the Community During Flu Vaccination